Genes or environment to determine alcoholic liver disease and non‐alcoholic fatty liver disease
暂无分享,去创建一个
[1] R. González-Sarmiento,et al. -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. , 2005, Alcoholism, clinical and experimental research.
[2] J. Grove,et al. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. , 1998, Pharmacogenetics.
[3] D. Pessayre,et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. , 2001, Gastroenterology.
[4] S. Uchida,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.
[5] A. Lonardo,et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.
[6] G. Omenn,et al. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. , 1981, Alcoholism, clinical and experimental research.
[7] I. Roberts-Thomson,et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis , 2001, Gut.
[8] F. Chang,et al. Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis , 2000, American Journal of Gastroenterology.
[9] David E. J. Jones,et al. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease , 2004, Hepatology.
[10] I. Leclercq,et al. Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.
[11] O. Yokosuka,et al. High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease , 1996, Hepatology.
[12] B. Grant,et al. The critical dimension of ethnicity in liver cirrhosis mortality statistics. , 2001, Alcoholism, clinical and experimental research.
[13] P. Bedossa,et al. Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.
[14] Mauro Santos,et al. Genetic polymorphism of alcohol dehydrogenase in europeans: TheADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1 , 2000, Hepatology.
[15] J. Peters,et al. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. , 2000, Pharmacogenetics.
[16] David C. Jones,et al. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease , 2003, Hepatology.
[17] G. Musso,et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.
[18] J. Grove,et al. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease , 2000, Gut.
[19] C. Clark,et al. Trends in alcohol-related problems among whites, blacks, and Hispanics: 1984-1995. , 1998, Alcoholism, clinical and experimental research.
[20] S. Horwitz,et al. Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.
[21] L. N. Valenti,et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease , 2002 .
[22] S. Caldwell,et al. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.
[23] J. Durbec,et al. Diet and alcohol in liver cirrhosis: a case-control study. , 1990, European journal of clinical nutrition.
[24] C. Day. From fat to inflammation. , 2006, Gastroenterology.
[25] I. Wanless,et al. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.
[26] A. Gasbarrini,et al. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test , 2003, American Journal of Gastroenterology.
[27] A. Andriulli,et al. Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. , 2001, Journal of hepatology.
[28] C. Fan,et al. Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase , 1998, The Journal of Biological Chemistry.
[29] Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001 .
[30] Rahul Krishnarao Patil,et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.
[31] G. Marchesini,et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.
[32] T. Mak,et al. CTLA‐4, a Negative Regulator of T‐Lymphocyte Activation , 1996, Immunological reviews.
[33] C. Day,et al. Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease , 2003 .
[34] J. Grove,et al. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis , 1997, Hepatology.
[35] C. Day,et al. Alcoholic liver disease: new insights into mechanisms and preventative strategies. , 2001, Trends in molecular medicine.
[36] J. Dixon,et al. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.
[37] J. Kench,et al. Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.
[38] Y. Chao,et al. Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients , 1997, Hepatology.
[39] J. Patrie,et al. Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.
[40] C. Day,et al. Hepatic steatosis: Innocent bystander or guilty party? , 1998, Hepatology.
[41] S. Aricó,et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. , 2004, Alcohol and alcoholism.
[42] K K Kidd,et al. Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. , 1999, American journal of human genetics.
[43] M. Vidali,et al. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. , 2002, Hepatology.
[44] Luc J. Smink,et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.
[45] M. Perola,et al. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease , 2001, Hepatology.
[46] M. Saboorian,et al. Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.
[47] J. Grove,et al. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease , 1998, Gut.
[48] D. Brenner,et al. Estriol sensitizes rat Kupffer cells via gut-derived endotoxin. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[49] G. Brandi,et al. Drinking habits as cofactors of risk for alcohol induced liver damage , 1997, Gut.
[50] C. Day. Pathogenesis of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.
[51] D. Schwartz,et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans , 2000, Nature Genetics.
[52] J. Dixon,et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. , 2003, Journal of hepatology.
[53] F. Capron,et al. Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.
[54] P. Moulin,et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes , 2000, Diabetologia.
[55] C. Day,et al. Candidate gene case-control association studies: advantages and potential pitfalls. , 2001, British journal of clinical pharmacology.
[56] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[57] C. Day. CD14 promoter polymorphism associated with risk of NASH , 2002 .
[58] P. Ward,et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.
[59] H. Shimano,et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP‐1 suppression , 2003, Hepatology.
[60] P. Holt,et al. A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. , 1999, American journal of respiratory cell and molecular biology.
[61] Yu Wang,et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.
[62] J. Patrie,et al. Is NASH underdiagnosed among African Americans , 2002 .
[63] T. Sørensen,et al. Lower risk for alcohol‐induced cirrhosis in wine drinkers , 2002, Hepatology.
[64] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.